DA Davidson lowered the firm's price target on LiveRamp to $35 from $45 and keeps a Buy rating on the shares. The company posted a beat on both the top and bottom line this quarter, but left the FY26 guide unchanged due to the timing of certain project based expenses falling into Q4 and softer marketplace growth vs. management expectations, the analyst tells investors in a research note.
